BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
BioXcel Therapeutics (BTAI) PT Lowered to $7 at BofA Securities
March 13, 2024 6:13 AM EDTBofA Securities analyst Geoff Meacham lowered the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "BioXcel announced a 4Q23 update as the company continues to finalize the clinical programs (see report) designed... More
